PIQ (ASX) Ann: Study shows diabetes drug improves PromarkerD risk scores

Originally posted by Owl vs Fox: ↑

Hi Scotty,

Approved for use in Australia, but the reason Janssen withdrew it above, it all came down to the Australian Govt not wanting to subsidise the cost on the PBS without a 40% price cut.

This may change, initially at this time, SGLT2is were for glycaemic control only. The cardiorenal benefits were not in the equation.

Now with cardiorenal benefits demonstrated in a multitude of studies & drugs becoming less costly as time goes on and market competition. Cost vs benefit, a better argument for subsidising on the PBS with more indications/benefit.

There are other SGLT2is now available in Australia with comparable costs. As usual with newer drugs & indivations, we are miles behind the 8 ball in Australia.

It can be a battle to get higher cost drugs onto the PBS, they are approved for use, but out of reach of most of us without being subsidised.

Regardless, it doesn’t change PromarkerD utility as a prognostic test for Australians.

Clinical guidelines show evidence for using this class of drugs. A recent article from Royal Australian College of General Practitioners (RACGP):

https://www1.racgp.org.au/getattachment/3e2b9a1c-6ed5-45e2-b4e3-7f07d08efae6/Use-of-sodium-glucose-co-transporter-2-inhibitors.aspx

Having a potential clinical tool (CDx) to monitor the benefits for patients, when to potentially start them on the drug (Prognostic risk score), I think could also be a game changer.

GLTAH

Expand

Hi Owl, Sincere thanks for taking the time to provide a very thorough response to my query. Your insight and knowledge of PIQ is of great benefit to many to less experienced investors in this area.

Originally posted by Owl vs Fox: ↑

Hi Scotty,

Approved for use in Australia, but the reason Janssen withdrew it above, it all came down to the Australian Govt not wanting to subsidise the cost on the PBS without a 40% price cut.

This may change, initially at this time, SGLT2is were for glycaemic control only. The cardiorenal benefits were not in the equation.

Now with cardiorenal benefits demonstrated in a multitude of studies & drugs becoming less costly as time goes on and market competition. Cost vs benefit, a better argument for subsidising on the PBS with more indications/benefit.

There are other SGLT2is now available in Australia with comparable costs. As usual with newer drugs & indivations, we are miles behind the 8 ball in Australia.

It can be a battle to get higher cost drugs onto the PBS, they are approved for use, but out of reach of most of us without being subsidised.

Regardless, it doesn’t change PromarkerD utility as a prognostic test for Australians.

Clinical guidelines show evidence for using this class of drugs. A recent article from Royal Australian College of General Practitioners (RACGP):

https://www1.racgp.org.au/getattachment/3e2b9a1c-6ed5-45e2-b4e3-7f07d08efae6/Use-of-sodium-glucose-co-transporter-2-inhibitors.aspx

Having a potential clinical tool (CDx) to monitor the benefits for patients, when to potentially start them on the drug (Prognostic risk score), I think could also be a game changer.

GLTAH

Expand

Originally posted by Owl vs Fox: ↑

Hi Scotty,

Approved for use in Australia, but the reason Janssen withdrew it above, it all came down to the Australian Govt not wanting to subsidise the cost on the PBS without a 40% price cut.

This may change, initially at this time, SGLT2is were for glycaemic control only. The cardiorenal benefits were not in the equation.

Now with cardiorenal benefits demonstrated in a multitude of studies & drugs becoming less costly as time goes on and market competition. Cost vs benefit, a better argument for subsidising on the PBS with more indications/benefit.

There are other SGLT2is now available in Australia with comparable costs. As usual with newer drugs & indivations, we are miles behind the 8 ball in Australia.

It can be a battle to get higher cost drugs onto the PBS, they are approved for use, but out of reach of most of us without being subsidised.

Regardless, it doesn’t change PromarkerD utility as a prognostic test for Australians.

Clinical guidelines show evidence for using this class of drugs. A recent article from Royal Australian College of General Practitioners (RACGP):

https://www1.racgp.org.au/getattachment/3e2b9a1c-6ed5-45e2-b4e3-7f07d08efae6/Use-of-sodium-glucose-co-transporter-2-inhibitors.aspx

Having a potential clinical tool (CDx) to monitor the benefits for patients, when to potentially start them on the drug (Prognostic risk score), I think could also be a game changer.

GLTAH

Expand

No.	Vol.	Price($)
1	1000	58.0¢

No.

Vol.

Price($)

1000

58.0¢

Price($)	Vol.	No.
59.0¢	4075	2

Price($)

Vol.

No.

59.0¢

4075

No.	Vol.	Price($)
1	1000	0.580
1	16610	0.575
2	33000	0.570
1	1207	0.560
12	61191	0.550

No.

Vol.

Price($)

1000

0.580

16610

0.575

33000

0.570

1207

0.560

61191

0.550

Price($)	Vol.	No.
0.590	4075	2
0.595	12245	1
0.600	29022	5
0.610	300	1
0.625	16510	1

Price($)

Vol.

No.

0.590

4075

0.595

12245

0.600

29022

0.610

300

0.625

16510

(20min delay)
Last 58.0¢		Change -0.020(3.33%)		Mkt cap ! $77.29M

Open	High	Low	Value	Volume
60.0¢	60.0¢	57.5¢	$39.83K	68.28K

Ann: Study shows diabetes drug improves PromarkerD risk scores, page-36

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

Cauldron discovers shallow uranium up to 2km at WA's Yanrey

ASX Market Open: Australian bourse to fall as subdued Wall Street awaits rate cut decision | September 18, 2024

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Study shows diabetes drug improves PromarkerD risk scores, page-36

Top Stories

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

Cauldron discovers shallow uranium up to 2km at WA's Yanrey

ASX Market Open: Australian bourse to fall as subdued Wall Street awaits rate cut decision | September 18, 2024

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News